Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Original Research

Koshi Yokomura¹  Toshihiro Shirai¹  Takashi Yamada¹  Naoki Koshimizu¹  Masaki Sato¹  Mikio Toyoshima¹  Hisano Ohba¹  Shigeki Kuroishi¹  Masafumi Masuda¹  Jun Sato¹  Noriyuki Enomoto²  Yutaro Nakamura²  Naoki Inui²  Masato Karayama²  Tomoyuki Fujisawa²  Hideki Yasui²  Takafumi Suda² 

[1] Hamamatsu Shizuoka Respiratory Group, Hamamatsu, Japan;Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan;Hamamatsu Shizuoka Respiratory Group, Hamamatsu, Japan;

关键词: Chronic obstructive pulmonary disease;    exacerbation;    fluticasone–salmeterol;    inhaled corticosteroid;    pneumonia;   

DOI  :  10.1177/1179548418771702

 received in 2017-09-25, accepted in 2018-03-12,  发布年份 2018

来源: Sage Journals

【 摘 要 】

Inhaled corticosteroids are widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, their use has been questioned for appropriate dose and a possible increased risk of pneumonia. Here, we reviewed patients with COPD who had received fluticasone–salmeterol combination treatment using data from a linked electronic medical record database. A total of 180 patients received salmeterol with 250 µg fluticasone propionate twice daily and 78 received salmeterol and 100 µg fluticasone propionate twice daily. In both groups, there was no difference in the improved forced expiratory volume in 1 second and COPD assessment test score and the proportion of patients with exacerbations. Although the incidence of common toxicity was approximately equal, that of pneumonia was much higher in the 250 µg group (8.9% vs 1.3%, P=.01). The beneficial effects of inhaled corticosteroids might be obtained at lower doses.

【 授权许可】

CC BY-NC   
© The Author(s) 2018

【 图 表 】

Figure 10.

Figure 2

Figure 1.